LEFKOFF KYLE 4

4 · ARRAY BIOPHARMA INC · Filed Feb 8, 2019

Form 4

Period: 2019-02-06

Director

Transactions

Exercise/Conversion
Common Stock
2019-02-06$10.47/sh+25,000$261,750→ 47,720 total
Sale
Common Stock
2019-02-06$20.82/sh−5,000$104,121→ 25,000 total(indirect: See footnote)
Sale
Common Stock
2019-02-06$20.85/sh−5,000$104,261→ 20,000 total(indirect: See footnote)
Sale
Common Stock
2019-02-06$20.51/sh−25,000$512,693→ 22,720 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-02-06−25,000→ 0 total
Exercise: $10.47Exp: 2027-10-26→ Common Stock (25,000 underlying)

Holdings

Footnotes (7)

[F1]The price reported for these shares is the weighted average sale price of transactions made at prices from $20.50 to $20.58. Details of actual prices for shares sold are available from the Reporting Person upon request.
[F2]The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act.
[F3]The price reported for these shares is the weighted average sale price of transactions made at prices from $20.785 to $20.834. Details of actual prices for shares sold are available from the Reporting Person upon request.
[F4]Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children.
[F5]The price reported for these shares is the weighted average sale price of transactions made at prices from $20.805 to $20.864. Details of actual prices for shares sold are available from the Reporting Person upon request.
[F6]Comprised of common stock held by BV Partners III Profit Sharing account for the benefit of the Reporting Person.
[F7]The options vested on October 26, 2018.

Documents

1 file